Abstract
The permeability transition pore (PTPC), a polyprotein complex, participates in the mitochondrial homeostasis as well as in the mitochondrial phase of the intrinsic pathway of apoptosis. It integrates multiple death signals including alterations of the intracellular milieu, translocation of pro-apoptotic members of the Bax/Bcl-2 family, p53, and viral proteins. As a consequence, PTPC can act as a coordinator of the pro-apoptotic mitochondrial membrane permeabilization process and the release of pro-apoptotic intermembrane space proteins into the cytosol. Moreover, the deregulation of PTPC has been involved in several major human pathologies such as cancer, neurodegeneration, ischemia/reperfusion, aging, as well as hepatotoxicity. Therefore, PTPC has emerged as a promising potential therapeutic target. Here, we will review the current knowledge concerning the two opposite functions of the PTPC and its implication in various pathologies. We will discuss the possibility to target this complex with peptides to modulate apoptosis in an innovative therapeutic perspective.
Keywords: ATP cell content, inner mitochondrial membrane (IM), Cancer, Ischemic reperfusion injury, voltage-dependent anion channel (VDAC)
Current Pharmaceutical Design
Title: Peptido-Targeting of the Mitochondrial Transition Pore Complex for Therapeutic Apoptosis Induction
Volume: 12 Issue: 34
Author(s): Aurelien Deniaud, Johan Hoebeke, Jean-Paul Briand, Sylviane Muller, Etienne Jacotot and Catherine Brenner
Affiliation:
Keywords: ATP cell content, inner mitochondrial membrane (IM), Cancer, Ischemic reperfusion injury, voltage-dependent anion channel (VDAC)
Abstract: The permeability transition pore (PTPC), a polyprotein complex, participates in the mitochondrial homeostasis as well as in the mitochondrial phase of the intrinsic pathway of apoptosis. It integrates multiple death signals including alterations of the intracellular milieu, translocation of pro-apoptotic members of the Bax/Bcl-2 family, p53, and viral proteins. As a consequence, PTPC can act as a coordinator of the pro-apoptotic mitochondrial membrane permeabilization process and the release of pro-apoptotic intermembrane space proteins into the cytosol. Moreover, the deregulation of PTPC has been involved in several major human pathologies such as cancer, neurodegeneration, ischemia/reperfusion, aging, as well as hepatotoxicity. Therefore, PTPC has emerged as a promising potential therapeutic target. Here, we will review the current knowledge concerning the two opposite functions of the PTPC and its implication in various pathologies. We will discuss the possibility to target this complex with peptides to modulate apoptosis in an innovative therapeutic perspective.
Export Options
About this article
Cite this article as:
Deniaud Aurelien, Hoebeke Johan, Briand Jean-Paul, Muller Sylviane, Jacotot Etienne and Brenner Catherine, Peptido-Targeting of the Mitochondrial Transition Pore Complex for Therapeutic Apoptosis Induction, Current Pharmaceutical Design 2006; 12 (34) . https://dx.doi.org/10.2174/138161206779010530
DOI https://dx.doi.org/10.2174/138161206779010530 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Gene Expression by Progesterone in Cancer Cells: Effects on Cyclin D1, EGFR and VEGF
Mini-Reviews in Medicinal Chemistry Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Current Signal Transduction Therapy The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
Current Signal Transduction Therapy The proNGF-p75NTR-Sortilin Signalling Complex as New Target for the Therapeutic Treatment of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy Recent Advances in Oncological Submissions of Dendrimer
Current Pharmaceutical Design Lessons Learned from the Irinotecan Metabolic Pathway
Current Medicinal Chemistry The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design Image Integration Procedures in Multisensory Medical Images: A Comprehensive Survey of the State-of-the-art Paradigms
Current Medical Imaging Nanotools for the Delivery of Antimicrobial Peptides
Current Drug Targets Fluoride Effects: The Two Faces of Janus
Current Medicinal Chemistry Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology Fgf10: A Paracrine-Signaling Molecule in Development, Disease, and Regenerative Medicine
Current Molecular Medicine Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Protein & Peptide Letters Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry Imaging in the Age of Molecular Medicine: Monitoring of Anti-Angiogenic Treatments
Current Pharmaceutical Biotechnology Current Overview of Inorganic Nanoparticles for the Treatment of Central Nervous System (CNS) Diseases
Current Nanomaterials Adenovirus Vectors Composed of Subgroup B Adenoviruses
Current Gene Therapy HR MAS MR Spectroscopy in Metabolic Characterization of Cancer
Current Topics in Medicinal Chemistry